In June, ProSomnus announced plans for a new 32,219-square-foot facility to be located in Hacienda. The facility will serve as the company’s global headquarters and manufacturing center of excellence. The company is a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA).

ProSomnus is the first manufacturer of precision, mass-customized oral appliance therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes, according to company officials. With more than 150,000 patients treated, ProSomnus’s devices are the most prescribed oral appliance therapy in the U.S.

ProSomnus’s relocation will be from an existing Hacienda site. The move will quintuple manufacturing capacity, enabling ProSomnus to meet the rapidly growing demand for the company’s FDA-cleared oral appliance therapy devices. ProSomnus expects to begin operations at the facility in January 2023.

In addition to expanding capacity, the purpose-built facility will allow ProSomnus, a pioneer in precision oral appliance therapy, to enhance production workflows. The facility will be optimized for mass-customized manufacturing, artificial intelligence-driven medical device design, and 3D robotic milling, with the intention of enhancing production flow, product quality, manufacturing service, and logistics.

“Our new Pleasanton facility will be engineered to improve productivity and process efficiency by applying the latest technologies and lean workflow,” according to Sung Kim, Co-Founder and Chief Technology Officer of ProSomnus. “Our enhanced manufacturing facility will allow the advancement of disruptive ideas that turn into innovative products.”

The new facility location in Hacienda was selected with employees, customers, and suppliers in mind, according to company officials. They noted that the facility places employees within walking distance of rail and bus commuter centers, offers easy access to two major highways, and is near key shipping and logistics partners. Employees will enjoy outdoor break space and easy access to many local shops and restaurants.

“Expanding our footprint in a logistical hub such as Pleasanton is a critical step in making our patient-preferred Oral Appliance Therapy devices available to as many patients as possible,” according to Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus. “Our new facility will help ProSomnus meet the growing, global demand for our medical devices, optimize our workflows, offer new jobs for the local economy, and provide employees with new career opportunities.”

In other news, ProSomnus entered a definitive merger agreement with Lakeshore Acquisition I Corp., a special purpose acquisition company, in May 2022. Upon closing, which is anticipated to be no later than December 2022, the combined company is expected to change its name to ProSomnus, Inc. and its Class A common stock is expected to be traded on the Nasdaq Capital Market under the symbol “OSA”.

For more information about ProSomnus, please visit www.prosomnus.com.